Today's News Flashes
Embryonic Switch for Cancer Stem Cell Generation
Nov. 30, 2015 - Decreases in a specific group of proteins trigger changes in the cancer microenvironment that accelerate growth and development of therapy-resistant cancer stem cells (CSCs), a team of researchers ... (More)
Nov. 30, 2015 - Decreases in a specific group of proteins trigger changes in the cancer microenvironment that accelerate growth and development of therapy-resistant cancer stem cells (CSCs), a team of researchers ... (More)
Leukemia: Why Is New Drug So Effective?
Nov. 30, 2015 - When preliminary tests show that a new drug has remarkable effectiveness against a lethal illness, everyone wants to know ... (More)
Nov. 30, 2015 - When preliminary tests show that a new drug has remarkable effectiveness against a lethal illness, everyone wants to know ... (More)
Air Pollution and Cardiovascular Disease
Nov. 25, 2015 - Air pollution is a major risk factor for cardiovascular disease, and some people may be more susceptible to its effects than others. Investigators ...(More)
Nov. 25, 2015 - Air pollution is a major risk factor for cardiovascular disease, and some people may be more susceptible to its effects than others. Investigators ...(More)
Promising New Melanoma Drug Identified
Nov. 25, 2015 - A new, first-in-class compound halts tumor growth by disrupting protein production, report scientists, who say that the new drug may show promise for treating skin cancers that are resistant or ...(More)
Nov. 25, 2015 - A new, first-in-class compound halts tumor growth by disrupting protein production, report scientists, who say that the new drug may show promise for treating skin cancers that are resistant or ...(More)
Pembrolizumab in Advanced Melanoma: Added Benefit for Certain Patients
Nov. 23, 2015 - Certain adults with pretreatment have fewer side effects under pembrolizumab. Treatment-naive patients without tumor mutation survive longer and have better social participation, report ... (More)
Nov. 23, 2015 - Certain adults with pretreatment have fewer side effects under pembrolizumab. Treatment-naive patients without tumor mutation survive longer and have better social participation, report ... (More)
No hay comentarios:
Publicar un comentario